| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price ...
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $...
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced the publication of a ...
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced that, through its lon...
Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bought AMD, Pacific Biosciences,...